Article Text

Download PDFPDF

Bisphosphonates reduce the risk of knee replacement: we need more analyses!
  1. Hui-Zi Li,
  2. Xiang-He Xu,
  3. Hua-Ding Lu
  1. Department of Orthopaedics, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
  1. Correspondence to Professor Hua-Ding Lu, Department of Orthopaedics, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China; johnniehuading{at}163.com

Statistics from Altmetric.com

With great interest, we read the recent article by Neogi et al entitled, ‘Effect of bisphosphonates on knee replacement (KR) surgery’.1 In the study, the authors concluded that in this population-based cohort of older women with incident knee osteoarthritis (OA), those with incident bisphosphonate users had lower risk of KR than non-users of bisphosphonates, which was further supported by another large cohort study.2 The strengths of this study include a propensity score-matched cohort design, Cox proportional hazards regression to control for potential confounders and sensitivity analyses focused on residual confounding. Meanwhile, the authors acknowledged the limitations of their work. We applaud and congratulate their important work for clinical practice. However, several important points should be further discussed.

Generally, determinants of patient preferences for KR are OA severity, the level of knee pain, disability, and the weakness of quality of life, and more importantly, their willingness and access to KR. In the current study, authors tended to agree that reduced risk of KR has resulted from weakened OA progression after bisphosphonates use. However, recent high-level evidence indicated that bisphosphonates neither provide pain relief and function improvement nor radiographic progression in knee OA.3 4 Therefore, we wonder that bisphosphonates may affect the willingness and access to KR of patients with OA, thus reducing the risk of KR. Actually, many clinical and sociocultural factors, such as racial differences (African Americans and whites), social support and an educational intervention included a decision aid, have vital important influence on patient preferences for KR.5–7 More importantly, a recent study revealed that patient preferences for KR were strongly associated with knee pain severity in patients with OA with health insurance, but their inverse relationship disappeared in patients without health insurance.8 Also, another study suggested that despite worse baseline knee pain and function, black participants had much lower adjusted risk of having total KR (TKR) than white participants.9 Thus, these indicated that sociocultural factors, but not OA severity, may have more significant influence on the willingness and access to KR. However, Neogi and colleagues seemed to ignore these important sociocultural factors in Cox proportional hazards regression, propensity score model and sensitivity analyses. We strongly recommend additional analyses based on aforementioned risk factors, which may further increase the robustness and credibility of the current study.

Additionally, the authors assessed the influence of bisphosphonates use on the risk of KR in patients with OA. However, there were no any data involving the baseline characteristics of OA severity, the level of knee pain, disability and the weakness of quality of life between both cohorts. Moreover, the influence of the dose, route, time point or measuring instrument of bisphosphonates administration on the risk of KR was unclear, so further subgroups should be warranted. Meanwhile, the primary outcome (the risk of KR) may be involved in many similar terms, such as TKR, revision KR, hemi-KR or KR in both knees. As with us, some readers may be confused about the notion. Therefore, the primary outcome should be clearly defined.

To sum up, we respect the great work done by the authors, but the study should be interpreted with the aforementioned limitations and further analyses should be performed.

References

View Abstract

Footnotes

  • Funding The study was funded by the national natural science foundation of China (No. 81772384; 81572174).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles